Stocks Near Their 52-Week High — Financial View · Pharmaceutical Preparations
42 stocks match the Stocks Near Their 52-Week High screen. Stocks trading within 10% of their 52-week high — at or below it, not necessarily at a new one — largest first. Financial columns. Filtered to Pharmaceutical Preparations. Data as of close · Checked
| LLY | Lilly (Eli) | $1.33T | 0.5% | 18.6% | 68.5% | 31.6% | 1.39 | 1.17 | 83.6% | — | 31.9% | 1418.07 | +0.62% | 192K |
| JNJ | Johnson & Johnson | $665.2B | 1.9% | 8.2% | 19.7% | 13.7% | 1.02 | 0.44 | 67.6% | — | 16.2% | 276.34 | +3.82% | 373K |
| ONC | Beone Medicines Ltd. | $558.0B | — | 7.1% | 12.7% | 11.0% | 3.40 | 0.15 | 88.9% | 15.1% | 10.7% | 377.48 | +6.36% | 40K |
| ABBV | AbbVie | $521.3B | 2.3% | 7.0% | — | — | 0.87 | — | 73.7% | 32.2% | 15.7% | 294.91 | +3.16% | 341K |
| MRK | Merck | $370.7B | 2.3% | 1.8% | 5.5% | 2.6% | 1.35 | 1.11 | 71.8% | — | 3.6% | 150.37 | +3.93% | 358K |
| PFE | Pfizer | $175.5B | 5.6% | 2.0% | 4.5% | 2.7% | 1.42 | 0.67 | 73.4% | — | 6.3% | 30.79 | +2.70% | 3.2M |
| VRTX | Vertex Pharmaceuticals | $139.2B | — | 12.1% | 19.0% | 16.3% | 2.34 | 0.17 | 85.5% | 33.2% | 30.7% | 549.07 | +3.37% | 82K |
| BMY | Bristol Myers Squibb | $131.2B | 3.9% | 10.4% | 39.5% | 14.0% | 1.59 | 1.82 | 69.2% | — | 18.5% | 64.20 | +4.04% | 482K |
| REGN | Regeneron Pharmaceuticals | $96.3B | 0.4% | 10.8% | 14.4% | 13.6% | 3.35 | 0.06 | — | 28.8% | 28.5% | 930.90 | -4.41% | 65K |
| TEVA | Teva Pharmaceutical Industries Ltd | $48.8B | — | 1.3% | 6.3% | 1.4% | 0.95 | 3.61 | 53.5% | 8.3% | 2.9% | 41.80 | -0.24% | 577K |
| RPRX | Royalty Pharma Plc | $30.1B | 1.4% | 3.5% | 6.9% | 3.7% | 1.29 | 0.88 | — | 57.1% | 25.7% | 67.56 | +1.82% | 202K |
| UTHR | United Therapeutics Corp | $25.9B | — | 17.5% | 19.6% | 19.6% | 4.61 | 0.12 | 86.3% | 41.4% | 38.6% | 607.43 | +0.95% | 68K |
| VTRS | Viatris | $22.1B | 2.5% | -10.0% | -24.6% | -13.6% | 1.58 | 0.81 | 34.9% | -0.6% | -24.7% | 19.25 | +1.61% | 631K |
| ELAN | Elanco Animal Health Inc | $12.6B | — | -1.5% | -3.0% | -1.9% | 2.05 | 0.56 | 55.4% | — | -4.0% | 25.31 | +2.97% | 920K |
| TGTX | Tg Therapeutics, Inc. | $9.4B | — | 26.9% | 73.1% | 32.7% | 4.27 | 1.23 | 82.4% | 17.1% | 55.2% | 61.68 | +1.49% | 76K |
| SYRE | Spyre Therapeutics, Inc. | $9.4B | — | -24.0% | -25.1% | -25.1% | 27.40 | 0.05 | — | — | — | 99.19 | -0.14% | 108K |
| KNSA | Kiniksa Pharmaceuticals International, Plc | $7.5B | — | 11.1% | 15.4% | 15.4% | 3.91 | 0.38 | 90.2% | 13.8% | 11.6% | 96.08 | +3.15% | 44K |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.4B | — | 4.2% | — | 6.0% | 2.20 | 77.83 | 39.3% | 14.6% | 5.0% | 19.97 | -1.29% | 237K |
| LGND | Ligand Pharmaceuticals Inc | $6.3B | — | 2.3% | 5.4% | 2.5% | 1.22 | 1.17 | — | 9.5% | 20.3% | 316.17 | +0.69% | 9K |
| ARQT | Arcutis Biotherapeutics, Inc. | $4.3B | — | 5.7% | 12.3% | 8.5% | 2.92 | 0.45 | 91.2% | 6.9% | 5.9% | 34.23 | +6.90% | 194K |
| OGN | Organon & Co. | $3.6B | 0.6% | 1.6% | 17.9% | 2.2% | 2.02 | 7.17 | 53.1% | — | 3.5% | 13.86 | +0.11% | 189K |
| BHC | Bausch Health Companies Inc. | $3.1B | — | -3.3% | — | — | 1.56 | — | — | 11.2% | -7.6% | 8.34 | +2.58% | 253K |
| SLN | Silence Therapeutics Plc | $2.8B | — | -56.3% | — | — | 7.42 | 1.77 | 85.9% | — | — | 19.79 | +0.00% | 70K |
| XNCR | Xencor Inc | $2.6B | — | -15.3% | -21.0% | -18.6% | 6.54 | 0.13 | — | -72.7% | -58.8% | 35.03 | +14.33% | 113K |
| PVLA | Palvella Therapeutics, Inc. | $2.3B | — | -24.3% | -28.4% | -28.4% | 21.18 | 0.17 | — | — | — | 162.66 | +6.31% | 34K |
| SEPN | Septerna, Inc. | $2.2B | — | -4.3% | -6.3% | -6.3% | 4.99 | 0.47 | — | -44.0% | -24.5% | 47.88 | +9.47% | 57K |
| ZYME | Zymeworks Inc. | $2.2B | — | -37.8% | — | — | 6.32 | 3.94 | — | -87.3% | -76.6% | 30.94 | +2.69% | 40K |
| XERS | Xeris Biopharma Holdings, Inc. | $1.9B | — | -4.2% | — | — | 1.45 | — | — | 10.9% | -5.1% | 10.46 | +0.97% | 234K |
| PCRX | Pacira Biosciences, Inc. | $1.5B | — | 1.2% | 2.2% | 1.4% | 5.04 | 0.54 | 79.2% | 2.7% | 2.0% | 36.42 | +0.10% | 165K |
| OPK | OPKO HEALTH, INC. | $1.3B | — | -7.9% | -13.3% | -9.3% | 4.97 | 0.43 | 46.2% | -25.5% | -29.5% | 1.79 | +3.47% | 218K |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.2B | — | 4.5% | 10.2% | 5.7% | 2.40 | 0.81 | 47.7% | 15.7% | 10.8% | 28.04 | +3.35% | 31K |
| RIGL | Rigel Pharmaceuticals Inc | $958M | — | 61.8% | 75.7% | 68.4% | 1.94 | 0.11 | 91.4% | 31.5% | — | 51.30 | +4.87% | 12K |
| VSTM | Verastem, Inc. | $894M | — | -98.2% | — | — | 2.25 | 0.81 | — | — | — | 9.87 | +0.87% | 240K |
| DMAC | DiaMedica Therapeutics Inc. | $582M | — | -83.4% | -97.9% | — | 6.72 | — | — | — | — | 10.79 | +7.68% | 30K |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $553M | — | 13.9% | 19.3% | 19.3% | 2.91 | 0.00 | 74.8% | 13.2% | 11.6% | 10.71 | +4.59% | 29K |
| RLYB | Rallybio Corp | $86M | — | 28.1% | 29.0% | 29.0% | 28.87 | 0.04 | — | — | — | 15.90 | +0.16% | 919 |
| GMAB | Genmab A/S | — | — | — | — | — | — | — | — | — | — | 55.08 | -0.74% | 328K |
| RDY | Dr Reddys Laboratories Ltd | — | — | — | — | — | — | — | — | — | — | 14.77 | +3.18% | 248K |
| TAK | Takeda Pharmaceutical Co Ltd | — | — | — | — | — | — | — | — | — | — | 21.07 | +1.47% | 205K |
| ASND | Ascendis Pharma A/S | — | — | — | — | — | — | — | — | — | — | 257.95 | +3.22% | 40K |
| SNY | Sanofi | — | — | — | — | — | — | — | — | — | — | 47.44 | +4.65% | 446K |
| NVS | Novartis Ag | — | — | — | — | — | — | — | — | — | — | 165.02 | +3.64% | 116K |
Source: SEC EDGAR/XBRL (fundamentals, shares) · Databento EQUS.MINI (EOD prices) · multiples, ratios & technicals computed by tradmap. Financials: Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it. A company reporting in another currency is shown in ≈ USD: its figures convert at the Federal Reserve H.10 rate of its price date (FRED), and without a rate its multiples are blank. This product uses the FRED® API but is not endorsed or certified by the Federal Reserve Bank of St. Louis. Informational only — not financial advice.